Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
OpenAI Rejects Apple Trade Secret Theft Claims 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Shein Shares Slide 9% in Hong Kong IPO Debut 
France Targets Shein, Temu With Fast-Fashion Fees 
Amazon Secures 200 MW Wind Power Deals in Sweden 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Add as a preferred source on Google
NESS ZIONA, Israel, March 26, 2018 -- Sol-Gel Technologies Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing audited financial statements for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on March 26, 2018, which is available on its website (http://www.sol-gel.com). Shareholders may receive a hard copy of the annual report free of charge upon request.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel’s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Patricia L. Bank
Westwicke Partners
+1-415-513-1284
[email protected]
